Eberly Hänel W, Sciscent Bao Y, Lorenz F Jeffrey, Rettig Eleni M, Goyal Neerav
Department of Otolaryngology Head and Neck Surgery, Penn State Milton S. Hershey Medical Center, Penn State College of Medicine, Hershey, PA 17033, USA.
Department of Otolaryngology Head and Neck Surgery, Brigham and Women's Hospital, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02108, USA.
Biomedicines. 2024 Feb 10;12(2):415. doi: 10.3390/biomedicines12020415.
Head and neck cancers (HNC) are a biologically diverse set of cancers that are responsible for over 660,000 new diagnoses each year. Current therapies for HNC require a comprehensive, multimodal approach encompassing resection, radiation therapy, and systemic therapy. With an increased understanding of the mechanisms behind HNC, there has been growing interest in more accurate prognostic indicators of disease, effective post-treatment surveillance, and individualized treatments. This chapter will highlight the commonly used and studied biomarkers in head and neck squamous cell carcinoma.
头颈癌（HNC）是一组生物学特性多样的癌症，每年有超过66万例新诊断病例。目前针对头颈癌的治疗需要采用包括手术切除、放射治疗和全身治疗在内的综合多模式方法。随着对头颈癌背后机制的认识不断加深，人们对更准确的疾病预后指标、有效的治疗后监测和个体化治疗的兴趣日益浓厚。本章将重点介绍头颈鳞状细胞癌中常用和研究较多的生物标志物。
